CXCR4 and myelodysplastic syndrome: We have recently shown that AML and high-risk MDS patients who receive an adoptive transfer of NK cells with high surface expression of the bone marrow (BM) homing CKR CXCR4 have a higher probability of reaching a complete remission compared to patients who receive NK cells with lower expression levels of CXCR43.